<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04574284</url>
  </required_header>
  <id_info>
    <org_study_id>TQB2450-II-08</org_study_id>
    <nct_id>NCT04574284</nct_id>
  </id_info>
  <brief_title>A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule in Subjects With Advanced Endometrial Cancer</brief_title>
  <official_title>A Open-label, Multicenter Phase II Study of TQB2450 Injection or Combined With Anlotinib Hydrochloride Capsule in Subjects With Advanced Endometrial Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chia Tai Tianqing Pharmaceutical Group Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chia Tai Tianqing Pharmaceutical Group Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study to evaluate the efficacy and safety of TQB2450 injection or combined with&#xD;
      anlotinib hydrochloride capsule in the treatment of recurrent or metastatic advanced&#xD;
      endometrial cancer.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 29, 2020</start_date>
  <completion_date type="Anticipated">April 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall response rate (ORR) evaluated by Independent Review Committee(IRC)</measure>
    <time_frame>up to 12 months</time_frame>
    <description>ORR defined as percentage of participants achieving complete response (CR) and partial response (PR), recorded from the first dose until the first documented progressive disease (PD) or death from any cause, based on IRC.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall response rate (ORR) evaluated by investigator</measure>
    <time_frame>up to 12 months</time_frame>
    <description>ORR defined as percentage of participants achieving complete response (CR) and partial response (PR), recorded from the first dose until the first documented progressive disease (PD) or death from any cause, based on investigator.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (DCR)</measure>
    <time_frame>up to 12 months</time_frame>
    <description>Percentage of participants achieving complete response (CR) and partial response (PR) and stable disease (SD).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DOR)</measure>
    <time_frame>up to 12 months</time_frame>
    <description>The time when the participants first achieved complete or partial remission to disease progression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival(PFS)</measure>
    <time_frame>up to 12 months</time_frame>
    <description>PFS defined as the time from randomization until the first documented progressive disease (PD) or death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival(OS)</measure>
    <time_frame>up to 18 months</time_frame>
    <description>OS defined as the time from randomization to death from any cause. Participants who do not die at the end of the extended follow-up period, or were lost to follow-up during the study, were censored at the last date they were known to be alive.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DOR rate (≥ 6 months)</measure>
    <time_frame>up to 6 months</time_frame>
    <description>The percentage of participants achieved complete or partial remission ≥ 6 months.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">196</enrollment>
  <condition>Advanced Endometrial Cancer</condition>
  <arm_group>
    <arm_group_label>TQB2450 + Anlotinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TQB2450 1200 mg administered intravenously (IV) on Day 1 of each 21-day cycle ,Anlotinib capsules 12 mg given orally, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TQB2450</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TQB2450 1200 mg administered intravenously (IV) on Day 1 of each 21-day cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Anlotinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Anlotinib capsules 12 mg given orally, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TQB2450</intervention_name>
    <description>TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors.</description>
    <arm_group_label>TQB2450</arm_group_label>
    <arm_group_label>TQB2450 + Anlotinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anlotinib</intervention_name>
    <description>A multi-target receptor tyrosine kinase inhibitor.</description>
    <arm_group_label>Anlotinib</arm_group_label>
    <arm_group_label>TQB2450 + Anlotinib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1. Understood and signed an informed consent form. 2. Eastern Cooperative Oncology&#xD;
             Group (ECOG) performance status of 0 to 1; Life expectancy ≥ 3 months.&#xD;
&#xD;
             3. Histopathologically confirmed recurrent or metastatic advanced endometrial cancer.&#xD;
&#xD;
             4. Has at least one measurable lesion. 5. Agree to provide tumor tissue samples for&#xD;
             MSI/MMR status detection. 6. Adequate laboratory indicators. 7. Serum or urine&#xD;
             pregnancy tests are negative within 7 days before randomization; Men and women should&#xD;
             agree to use effective contraception during the study period and after the end of the&#xD;
             study period within 6 months.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1.Concomitant disease and medical history:&#xD;
&#xD;
               1. Has diagnosed and/or treated additional malignancy within 3 years prior to&#xD;
                  randomization;&#xD;
&#xD;
               2. Pathological diagnosed as uterine sarcoma;&#xD;
&#xD;
               3. Has multiple factors affecting oral medication;&#xD;
&#xD;
               4. Unalleviated toxicity ≥ grade 1 due to any previous anticancer therapy.&#xD;
&#xD;
               5. Has received major surgical treatment, open biopsy and so on within 28 days&#xD;
                  before the start of the study.&#xD;
&#xD;
               6. Has a unhealed wound or fracture for a long time;&#xD;
&#xD;
               7. Has cerebrovascular accident, deep vein thrombosis and pulmonary embolism within&#xD;
                  6 months before the study;&#xD;
&#xD;
               8. Has uncontrollable pleural effusion, pericardial effusion, or ascites requiring&#xD;
                  recurrent drainage procedures;&#xD;
&#xD;
               9. Has a history of psychotropic substance abuse and unable to quit or mental&#xD;
                  disorders;&#xD;
&#xD;
              10. Has any serious and / or uncontrolled disease; 2. Tumor-related symptoms and&#xD;
                  treatment:&#xD;
&#xD;
               1. Has received surgery, chemotherapy, radiotherapy or other anticancer therapy&#xD;
                  within 4 weeks before the start of the study;&#xD;
&#xD;
               2. Has received proprietary Chinese medicine with anti-tumor indications in the NMPA&#xD;
                  approved drug instructions within 2 weeks before the start of the study;&#xD;
&#xD;
               3. Has received immunotherapeutic drugs against PD-1, PD-L1, CTLA-4 and other&#xD;
                  related drugs;&#xD;
&#xD;
               4. Has used antiangiogenic drugs such as bevacizumab, anlotinib, apatinib,&#xD;
                  lenvatinib, sorafenib, Sunitinib, regorafenib, fruquintinib, etc;&#xD;
&#xD;
               5. Has received hormone therapy for endometrial cancer within a week before the&#xD;
                  first dose ;&#xD;
&#xD;
               6. CT or MRI showed that the tumor had invaded the important blood vessels;&#xD;
&#xD;
               7. Has symptomatic central nervous system (CNS) disease and/or cancerous meningitis,&#xD;
                  pia mater disease; 3. Related to research and treatment:&#xD;
&#xD;
               1. Has received attenuated live vaccine within 28 days before randomization or&#xD;
                  planned to received attenuated live vaccine during the study period.&#xD;
&#xD;
               2. Has a history of severe allergic diseases.&#xD;
&#xD;
               3. Has active autoimmune diseases requiring systemic treatment occurred within 2&#xD;
                  years before the study.&#xD;
&#xD;
                  4. Has Participated in other clinical trials within 4 weeks before first dose. 5.&#xD;
                  According to the judgement of the investigators, there are other factors that may&#xD;
                  lead to the termination of the study.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Xiaohua Wu, Doctor</last_name>
    <email>wu.xh@fudan.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Anhui Provincial Hospital</name>
      <address>
        <city>Hefei</city>
        <state>Anhui</state>
        <zip>230001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Weidong Zhao, Doctor</last_name>
      <email>13955105591@163.com</email>
    </contact>
    <investigator>
      <last_name>Weidong Zhao, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Second Affiliated Hospital of Anhui Medical University</name>
      <address>
        <city>Hefei</city>
        <state>Anhui</state>
        <zip>230601</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Zhendong Chen</last_name>
      <email>ay2fychenzhendong@163.com</email>
    </contact>
    <investigator>
      <last_name>Zhendong Chen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beijing Chao-Yang Hospital, Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100016</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Shuzhen Wang, Doctor</last_name>
      <email>darrywang2003@163.com</email>
    </contact>
    <investigator>
      <last_name>Shuzhen Wang, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beijing Obstetrics and Gynecology Hospital, Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100016</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Wei Duan, Doctor</last_name>
      <email>wduan@263.net</email>
    </contact>
    <investigator>
      <last_name>Wei Duan, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Peking Union Medical College Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lingya Pan, Doctor</last_name>
      <email>lingyapan@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Lingya Pan, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tsinghua University Affiliated Beijing Tsinghua Changgung Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>101100</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Qinping Liao, Doctor</last_name>
      <email>13701124527@163.com</email>
    </contact>
    <investigator>
      <last_name>Qinping Liao, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beijing Luhe Hospital Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>101149</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dong Yan, Doctor</last_name>
      <email>yd15yt88@163.com</email>
    </contact>
    <investigator>
      <last_name>Dong Yan, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chongqing University Cancer Hospital</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <zip>400030</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dong Wang</last_name>
      <email>cqwindow120@163.com</email>
    </contact>
    <investigator>
      <last_name>Dong Wang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gansu Provincial Hospital</name>
      <address>
        <city>Lanzhou</city>
        <state>Gansu</state>
        <zip>730000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tiansheng Qing, doctor</last_name>
      <phone>0931-8281367</phone>
      <email>1689939406@qq.com</email>
    </contact>
    <investigator>
      <last_name>Tiansheng Qing, doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hongyi Cai, doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lanzhou University Second Hospital</name>
      <address>
        <city>Lanzhou</city>
        <state>Gansu</state>
        <zip>730030</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pengfei Sun, doctor</last_name>
      <email>sunpengfeiby@163.com</email>
    </contact>
    <investigator>
      <last_name>Pengfei Sun, doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gansu Province Maternity and Chid-care Hospital</name>
      <address>
        <city>Lanzhou</city>
        <state>Gansu</state>
        <zip>730050</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Qing Liu, doctor</last_name>
      <phone>0931-2231215</phone>
      <email>2305470816@qq.com</email>
    </contact>
    <investigator>
      <last_name>Qing Liu, doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sun Yat-sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510080</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jundong Li, Master</last_name>
      <email>lijd@sysucc.org.cn</email>
    </contact>
    <investigator>
      <last_name>Jundong Li, Master</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sun Yat-sen Memorial Hospital, Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510289</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bingzhong Zhang, Doctor</last_name>
      <email>13925063030@163.com</email>
    </contact>
    <investigator>
      <last_name>Bingzhong Zhang, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Guangxi Medical University Affiliated Tumor Hospital</name>
      <address>
        <city>Nanning</city>
        <state>Guangxi</state>
        <zip>530022</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Deisheng Yao, Doctor</last_name>
      <email>yaodeson@163.com</email>
    </contact>
    <investigator>
      <last_name>Deisheng Yao, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Affiliated Hospital of Hebei University</name>
      <address>
        <city>Baoding</city>
        <state>Hebei</state>
        <zip>071002</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Aimin Zang</last_name>
      <email>booszam@sina.com</email>
    </contact>
    <investigator>
      <last_name>Aimin Zang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Henan Cancer Hospital</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <zip>4500003</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Li Wang</last_name>
      <email>13837196622@163.com</email>
    </contact>
    <investigator>
      <last_name>Li Wang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hunan Cancer Hospital</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410013</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jing Wang, Doctor</last_name>
      <email>wangjing0081@hnca.org.cn</email>
    </contact>
    <investigator>
      <last_name>Jing Wang, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nanjing Drum Tower Hospital</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210009</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Huaijun Zhou, Doctor</last_name>
      <email>zhouhj2007@126.com</email>
    </contact>
    <investigator>
      <last_name>Huaijun Zhou, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Liaoning Cancer Hospital</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <zip>110041</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Danbo Wang, Doctor</last_name>
      <email>wangdanbo@cancerhosp-ln-cmu.com</email>
    </contact>
    <investigator>
      <last_name>Danbo Wang, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Binzhou Medical University Hospital</name>
      <address>
        <city>Binzhou</city>
        <state>Shandong</state>
        <zip>256600</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Fangling Ning</last_name>
      <email>ningfangling@126.com</email>
    </contact>
    <investigator>
      <last_name>Fangling Ning</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Linyi Cancer Hospital</name>
      <address>
        <city>Linyi</city>
        <state>Shandong</state>
        <zip>276034</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Xiumin Li</last_name>
      <email>lyzlyylxm@163.com</email>
    </contact>
    <investigator>
      <last_name>Xiumin Li</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Qingdao Central Hospital</name>
      <address>
        <city>Qingdao</city>
        <state>Shandong</state>
        <zip>266042</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Li Sun, Doctor</last_name>
      <email>ningfangling@126.com</email>
    </contact>
    <investigator>
      <last_name>Li Sun, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Weifang People's Hospital</name>
      <address>
        <city>Weifang</city>
        <state>Shandong</state>
        <zip>261000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Guohua Yu</last_name>
      <email>ghyry@126.com</email>
    </contact>
    <investigator>
      <last_name>Guohua Yu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yantai Yuhuangding Hospital</name>
      <address>
        <city>Yantai</city>
        <state>Shandong</state>
        <zip>264000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jianqing Hou, Doctor</last_name>
      <email>hjq63@126.com</email>
    </contact>
    <investigator>
      <last_name>Jianqing Hou, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Obstetrics &amp; Gynecology Hospital of Fudan University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200090</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaojun Chen, Doctor</last_name>
      <email>cxjlhjj@163.com</email>
    </contact>
    <investigator>
      <last_name>Xiaojun Chen, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fudan University Shanghai Cancer Center</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Xiaohua Wu, Doctor</last_name>
      <email>wu.xh@fudan.edu.cn</email>
    </contact>
    <investigator>
      <last_name>Xiaohua Wu, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Second Hospital of Shanxi Medical University</name>
      <address>
        <city>Taiyuan</city>
        <state>Shanxi</state>
        <zip>030001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Min Hao, Doctor</last_name>
    </contact>
    <investigator>
      <last_name>Min Hao, D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Xi'an People's Hospital</name>
      <address>
        <city>Xi'an</city>
        <state>Shanxi</state>
        <zip>710004</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Xinwen Fang, doctor</last_name>
      <email>xianxinwen@163.com</email>
    </contact>
    <investigator>
      <last_name>Xinwen Fang, doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>First Affiliated Hospital of Xi'an Jiaotong University</name>
      <address>
        <city>Xi'an</city>
        <state>Shanxi</state>
        <zip>710061</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ruifang An, Doctor</last_name>
      <email>anruifang@163.com</email>
    </contact>
    <investigator>
      <last_name>Ruifang An, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tianjin Central Hospital of Gynecology Obstetrics</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300052</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pengpeng Qu, Doctor</last_name>
      <email>qu.pengpeng@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Pengpeng Qu, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tianjin Medical University Cancer Institute &amp; Hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ke Wang, Master</last_name>
      <email>18622080116@163.com</email>
    </contact>
    <investigator>
      <last_name>Ke Wang, Master</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>First Affiliated Hospital, School of Medicine, Shihezi University</name>
      <address>
        <city>Shihezi</city>
        <state>Xinjiang Uygur Autonomous Region</state>
        <zip>832008</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ping Gong, Doctor</last_name>
      <email>18990195455@163.com</email>
    </contact>
    <investigator>
      <last_name>Ping Gong, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Xinjiang Medical University</name>
      <address>
        <city>Urumqi</city>
        <state>Xinjiang Uygur Autonomous Region</state>
        <zip>830000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Cailing Ma, Doctor</last_name>
      <email>mymcl@sina.com</email>
    </contact>
    <investigator>
      <last_name>Cailing Ma, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Xinjiang Medical University Affiliated Tumor Hospital</name>
      <address>
        <city>Urumqi</city>
        <state>Xinjiang Uygur Autonomous Region</state>
        <zip>830000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jianlin Yuan</last_name>
      <email>1499307418@qq.com</email>
    </contact>
    <investigator>
      <last_name>Jianlin Yuan</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gulina Kuerban</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Zhejiang Cancer Hospital</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hanmei Lou</last_name>
      <email>louhm@zjcc.org.cn</email>
    </contact>
    <investigator>
      <last_name>Hanmei Lou</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Taizhou Hospital of Zhejiang Province</name>
      <address>
        <city>Taizhou</city>
        <state>Zhejiang</state>
        <zip>317000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Haihua Yang, doctor</last_name>
      <phone>021-33189900</phone>
      <email>cxjlhjj@163.com</email>
    </contact>
    <investigator>
      <last_name>Haihua Yang, doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>September 30, 2020</study_first_submitted>
  <study_first_submitted_qc>September 30, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 5, 2020</study_first_posted>
  <last_update_submitted>August 17, 2021</last_update_submitted>
  <last_update_submitted_qc>August 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endometrial Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

